Cite
HARVARD Citation
Rivera, F. et al. (n.d.). 2014 Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC). European journal of cancer. pp. S332-S333. [Online].